REV1 and neoplasm: However, this study expands the significance of REV1’s role in cell cycle biology, specifically by triggering a G2/M arrest, with clinical implications for diseases, specifically cancer pathogenesis and resistance, given that REV1 targeting by the JH-RE-06 inhibitor is known to combat cancer chemoresistance [48], as reported for other tumor suppressor candidates [104,105].